Komipharm International Co., Ltd. (KOSDAQ:041960)
South Korea · Delayed Price · Currency is KRW 7,500.00
-360.00 (-4.58%)
At close: Feb 6, 2026
Komipharm International Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 56,302 | 58,779 | 42,647 | 39,801 | 35,847 | 37,160 |
Other Revenue | - | - | - | - | -0 | - |
| 56,302 | 58,779 | 42,647 | 39,801 | 35,847 | 37,160 | |
Revenue Growth (YoY) | 3.25% | 37.83% | 7.15% | 11.03% | -3.53% | 4.71% |
Cost of Revenue | 38,543 | 37,146 | 30,120 | 28,485 | 24,741 | 23,857 |
Gross Profit | 17,759 | 21,633 | 12,527 | 11,316 | 11,107 | 13,303 |
Selling, General & Admin | 11,844 | 11,741 | 10,459 | 10,004 | 9,127 | 9,907 |
Research & Development | 1,831 | 2,466 | 5,945 | 2,536 | 5,117 | 3,266 |
Amortization of Goodwill & Intangibles | 395.65 | 253.81 | 86.22 | 132.42 | 146.36 | 153.55 |
Other Operating Expenses | 98.92 | 236.76 | 243.5 | 251.86 | 220.89 | 215.79 |
Operating Expenses | 15,181 | 15,440 | 18,800 | 15,119 | 16,397 | 15,478 |
Operating Income | 2,578 | 6,193 | -6,273 | -3,804 | -5,291 | -2,175 |
Interest Expense | -2,906 | -3,206 | -2,552 | -2,216 | -1,657 | -1,549 |
Interest & Investment Income | 843.29 | 707.18 | 678.36 | 227.68 | 140.21 | 165.33 |
Currency Exchange Gain (Loss) | 615.84 | 1,109 | 235.11 | 474.93 | 1,129 | -217.15 |
Other Non Operating Income (Expenses) | -2,341 | 2,781 | 2,106 | 940.07 | 51.94 | -447.5 |
EBT Excluding Unusual Items | -1,210 | 7,585 | -5,805 | -4,377 | -5,626 | -4,224 |
Gain (Loss) on Sale of Investments | -58.65 | -123.27 | 248.7 | - | 13.59 | 122.52 |
Gain (Loss) on Sale of Assets | -171.71 | 9,073 | 64.42 | -2.43 | 0.81 | 144.51 |
Asset Writedown | -1,845 | -1,845 | -247.4 | -3,100 | -323 | - |
Pretax Income | -3,445 | 14,690 | -5,739 | -7,480 | -5,934 | -3,957 |
Income Tax Expense | - | - | 171.15 | - | - | - |
Earnings From Continuing Operations | -3,445 | 14,690 | -5,911 | -7,480 | -5,934 | -3,957 |
Minority Interest in Earnings | 905.3 | -1,577 | 1,932 | 965.91 | 1,475 | 1,141 |
Net Income | -2,540 | 13,113 | -3,979 | -6,514 | -4,459 | -2,816 |
Net Income to Common | -2,540 | 13,113 | -3,979 | -6,514 | -4,459 | -2,816 |
Shares Outstanding (Basic) | 70 | 70 | 70 | 70 | 70 | 70 |
Shares Outstanding (Diluted) | 70 | 70 | 70 | 70 | 70 | 70 |
Shares Change (YoY) | 1.54% | -0.66% | -0.18% | 0.01% | 0.09% | 0.37% |
EPS (Basic) | -36.22 | 188.17 | -56.72 | -92.68 | -63.45 | -40.10 |
EPS (Diluted) | -36.39 | 188.00 | -57.00 | -93.00 | -63.64 | -40.10 |
Free Cash Flow | -361.45 | 7,802 | -3,437 | -2,656 | -2,069 | -1,631 |
Free Cash Flow Per Share | -5.16 | 111.95 | -48.99 | -37.78 | -29.45 | -23.22 |
Gross Margin | 31.54% | 36.80% | 29.37% | 28.43% | 30.98% | 35.80% |
Operating Margin | 4.58% | 10.54% | -14.71% | -9.56% | -14.76% | -5.85% |
Profit Margin | -4.51% | 22.31% | -9.33% | -16.37% | -12.44% | -7.58% |
Free Cash Flow Margin | -0.64% | 13.27% | -8.06% | -6.67% | -5.77% | -4.39% |
EBITDA | 5,662 | 9,293 | -2,744 | 22.34 | -1,708 | 1,565 |
EBITDA Margin | 10.06% | 15.81% | -6.43% | 0.06% | -4.76% | 4.21% |
D&A For EBITDA | 3,084 | 3,100 | 3,529 | 3,826 | 3,582 | 3,740 |
EBIT | 2,578 | 6,193 | -6,273 | -3,804 | -5,291 | -2,175 |
EBIT Margin | 4.58% | 10.54% | -14.71% | -9.56% | -14.76% | -5.85% |
Advertising Expenses | - | 408.7 | 256.75 | 227.89 | 206.18 | 153.12 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.